Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > ORGANIZATION
ORGANIZATION
- New PhRMA Chairman Tells Prime Minister Abe, Pro-Innovation Policies Key to Maintaining Japanese Healthcare System
May 16, 2013
- Kyokai Kenpo Launches Trial Notification Service on Copayment Differences between Original, Generic Anti-Allergy Drugs
May 8, 2013
- Vital-Net Pres. Suzuki Tipped to Be Next President of JPWA; Number of VPs to Be Increased to 5
May 2, 2013
- Itsuro Yoshida of Towa Pharmaceutical Expected to Take Over as Next President of JGA
April 25, 2013
- “Both Sides Need to Work Harder” to Reach Agreements on Delivery Prices: Mr Nakamura of NPhA
April 23, 2013
- JPMA to Call on Its Member Companies to Ask Lecturers at Seminars Sponsored by Them for Their Permission to Disclose COI-Related Information
April 22, 2013
- JPMA Reinstates MSD K.K. as Member After 22-Month Suspension
April 22, 2013
- Tug-of-War over “Conflicts of Interest” (1): Drug Makers, Doctors Remain Divided
April 18, 2013
- APAC to Draft Roadmap for Early Drug Application and Approval in Asia
April 16, 2013
- JPMA Eyes Joint Communications Campaigns for Transparency Guidelines with JMA, JAMS
April 12, 2013
- Pharma Officials Puzzled at Fuzzy Communications Provision in JPMA Code of Practice
April 1, 2013
- Keizai Doyukai Urges Government to Switch All Long-Listed Products to Generics to Cut Social Security Costs
March 29, 2013
- Survey by Japan Hospital Association Finds Big Increase in Accounts Receivable per Hospital in 2012
March 27, 2013
- FPMAJ to Set Up International Affairs Committee and Self-Medication Task Force
March 25, 2013
- JPMA Suspends Activities of Vice President Hasegawa for Six Months and Membership of Nihon Pharmaceutical
March 22, 2013
- JPMA Officially Decides on One-Year Postponement of Individual Payment Disclosures under Transparency Guidelines
March 22, 2013
- JPWA Vice President Ken Suzuki Expected to Lead JPWA After President Bessho’s Term Ends in May
March 22, 2013
- EFPIA Simulation: New Drug Market Up Mere 0.4 Trillion Yen by 2022 Even with Premium
March 19, 2013
- Transparency Guidelines: JPMA Proposes One-Year Hold on Disclosure of Individual Payments
March 18, 2013
- Japan Society of Generic Medicines Calls for 80% Generic Drug Share by Volume within 5 Years
March 8, 2013
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…